Business ❯ Healthcare ❯ Pharmaceuticals

Biopharmaceuticals

AbbVie Inc. Clinical Trials Oncology Drug Development Incyte Corporation Ardelyx, Inc. Telix Pharmaceuticals Limited Central Nervous System (CNS) Diseases Immunology Aurinia Pharmaceuticals Pfizer Inc. Genetic Medicine Bristol-Myers Squibb Company Breast Cancer Treatments Biosimilar Products

Telix Confirms Webcast Investor Sessions at Oppenheimer and TD Cowen Conferences

Executives will outline strategy with an update on the regulatory outlook.

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

BMO Raises AbbVie Target to $240 After Rinvoq Generic Dispute Is Resolved

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline